このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

パーキンソン病(PD)患者を対象としたブンタネタップの研究

2026年10月28日 更新者:Annovis Bio Inc.

パーキンソン病の参加者を対象としたBuntanetap治療の長期安全性を調査するオープンラベル臨床試験

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

調査の概要

詳細な説明

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

研究の種類

介入

入学 (推定)

500

段階

  • フェーズ2
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • 募集
        • University of Alabama at Birmingham
        • コンタクト:
        • 主任研究者:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City、Arizona、アメリカ、85351
        • 募集
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • 主任研究者:
          • Sara Dhanani, M.D.
        • コンタクト:
    • California
      • Fountain Valley、California、アメリカ、92708
        • 募集
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • 主任研究者:
          • Daniel Truong, M.D.
        • コンタクト:
          • Evan Moreno-Davis
          • 電話番号:714-378-5074
          • メール:evan@pmdi.org
    • Colorado
      • Englewood、Colorado、アメリカ、80113
        • 募集
        • Cenexel Rocky Mountain Clinical Research
        • コンタクト:
        • 主任研究者:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford、Connecticut、アメリカ、06824
        • 募集
        • New England Institute for Clinical Research (Ki Health Partners)
        • コンタクト:
        • 主任研究者:
          • Peter McAllister, M.D.
    • Florida
      • Aventura、Florida、アメリカ、33180
        • 募集
        • First Choice Neurology - Aventura Neurologic Associates
        • 主任研究者:
          • Jonathan Cross, M.D.
        • コンタクト:
      • Daytona Beach、Florida、アメリカ、32117
        • 募集
        • Arrow Clinical Trials
        • コンタクト:
        • 主任研究者:
          • David Billmeier, M.D.
      • DeLand、Florida、アメリカ、32720
        • 募集
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • 主任研究者:
          • Bruce Rankin, D.O.
        • コンタクト:
      • Miami、Florida、アメリカ、33172
      • Miami、Florida、アメリカ、33015
        • まだ募集していません
        • Ezy Medical Research Co.
        • コンタクト:
      • Ocala、Florida、アメリカ、34470
        • 募集
        • Renstar Medical Research
        • 主任研究者:
          • Annette Nieves, M.D.
        • コンタクト:
      • Tampa、Florida、アメリカ、33613
        • 募集
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • コンタクト:
        • 主任研究者:
          • Robert Hauser, M.D., MBA
      • Winter Park、Florida、アメリカ、32789
        • 募集
        • Conquest Research
        • コンタクト:
        • 主任研究者:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur、Georgia、アメリカ、30030
        • 募集
        • iResearch Atlanta
        • コンタクト:
        • 主任研究者:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis、Indiana、アメリカ、46256
        • 募集
        • Josephson Wallack Munshower Neurology, P.C.
        • 主任研究者:
          • Kristi George, M.D.
        • コンタクト:
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • 募集
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • コンタクト:
        • 主任研究者:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills、Michigan、アメリカ、48334
        • 募集
        • Quest Research Institute
        • 主任研究者:
          • Aaron Ellenbogen, D.O.
        • コンタクト:
    • New York
      • New York、New York、アメリカ、10019
        • 募集
        • Mount Sinai Hospital
        • 主任研究者:
          • Joohi Jimenez-Shahed, M.D.
        • コンタクト:
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • 募集
        • Duke Department of Neurosurgery
        • 主任研究者:
          • Kyle Mitchell, M.D.
        • コンタクト:
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • The Ohio State University Wexner Medical Center
        • 主任研究者:
          • Zachary Jordan, M.D.
        • コンタクト:
    • Oklahoma
      • Tulsa、Oklahoma、アメリカ、74136
        • 募集
        • The Movement Disorder Clinic of Oklahoma
        • コンタクト:
        • 主任研究者:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove、Pennsylvania、アメリカ、19090
        • 募集
        • Abington Neurology
        • 主任研究者:
          • David Weisman, M.D.
        • コンタクト:
    • South Carolina
      • Charleston、South Carolina、アメリカ、29401
        • 募集
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • コンタクト:
        • 主任研究者:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova、Tennessee、アメリカ、38018
        • 募集
        • Neurology Clinic, P.C.
        • コンタクト:
        • 主任研究者:
          • Kendrick Henderson, M.D.
      • Memphis、Tennessee、アメリカ、38157
        • 募集
        • Veracity Neuroscience LLC
        • コンタクト:
        • 主任研究者:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock、Texas、アメリカ、78681
        • 募集
        • Central Texas Neurology
        • コンタクト:
        • 主任研究者:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • 募集
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • 主任研究者:
          • Binit Shah, M.D.
        • コンタクト:
    • Washington
      • Spokane、Washington、アメリカ、99202
        • 募集
        • Inland Northwest Research
        • 主任研究者:
          • Jason Aldred, M.D.
        • コンタクト:
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Medical College of Wisconsin
        • コンタクト:
        • 主任研究者:
          • Karen Blindauer, M.D.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

実験的:Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety of buntanetap
時間枠:36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
時間枠:36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
時間枠:36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
時間枠:36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Laurie Sanders, Ph.D.、Duke Clinical Research Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月9日

一次修了 (推定)

2029年9月1日

研究の完了 (推定)

2029年11月1日

試験登録日

最初に提出

2025年11月26日

QC基準を満たした最初の提出物

2025年12月9日

最初の投稿 (実際)

2025年12月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月30日

QC基準を満たした最後の更新が送信されました

2026年10月28日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する